IRBM

Peptide-based solutions are redefining disease targeting—see our latest research at #BPS2024. From September 16-19, we’ll be at the 𝗕𝗼𝘂𝗹𝗱𝗲𝗿 𝗣𝗲𝗽𝘁𝗶𝗱𝗲 𝗦𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 in Colorado, presenting our work on “𝘋𝘦𝘴𝘪𝘨𝘯 𝘢𝘯𝘥 𝘌𝘷𝘢𝘭𝘶𝘢𝘵𝘪𝘰𝘯 𝘰𝘧 𝘊𝘺𝘤𝘭𝘪𝘤 𝘗𝘦𝘱𝘵𝘪𝘥𝘦𝘴 𝘛𝘢𝘳𝘨𝘦𝘵𝘪𝘯𝘨 𝘔𝘶𝘵𝘚β 𝘢𝘯𝘥 𝘔𝘶𝘵𝘓α 𝘊𝘰𝘮𝘱𝘭𝘦𝘹𝘦𝘴”, which focuses on Mismatch Repair (MMR) pathway inhibition, with implications for Huntington’s disease. Join us to explore these advancements and meet Emanuela Nizi, Luigi Abate, Balwant Patel, MBA, PhD., and Michael Ziebell. Our team will be available to discuss our peptide capabilities and opportunities for future collaboration. 🧪🔬 Boulder Peptide Foundation #PeptideScience #DrugDiscovery #IRBM

Surface Plasmon Resonance (𝗦𝗣𝗥) technology offers unparalleled insights into protein interactions, revealing dynamics that were 𝙥𝙧𝙚𝙫𝙞𝙤𝙪𝙨𝙡𝙮 𝙝𝙞𝙙𝙙𝙚𝙣. 🕵️ Join us at the 𝗗𝗶𝗣𝗜𝗔 conference in Kista, Sweden from September 9-12 for an immersive journey through the evolution of SPR, uncovering its past, present, and future applications. Nadine Alaimo will be there to share insights on the latest advancements and practical applications of SPR. She’ll present her poster, '𝘚𝘗𝘙 𝘛𝘦𝘤𝘩𝘯𝘰𝘭𝘰𝘨𝘺 𝘧𝘰𝘳 𝘵𝘩𝘦 𝘪𝘥𝘦𝘯𝘵𝘪𝘧𝘪𝘤𝘢𝘵𝘪𝘰𝘯 𝘰𝘧 𝘯𝘦𝘸 𝘵𝘩𝘦𝘳𝘢𝘱𝘦𝘶𝘵𝘪𝘤 𝘢𝘨𝘦𝘯𝘵𝘴 𝘧𝘳𝘰𝘮 𝘱𝘩𝘢𝘨𝘦 𝘥𝘪𝘴𝘱𝘭𝘢𝘺 𝘭𝘪𝘣𝘳𝘢𝘳𝘪𝘦𝘴,' showcasing how IRBM integrates SPR assays as a critical step in the screening funnel, enabling precise characterization of peptide and mAb leads identified through phage display screening. Catch her at one of the two poster sessions: 📅 September 10th: 16:00-17:00 📅 September 11th: 15:00-15:30 🔎 Dive deep into the mysteries of protein interactions and be part of the quest to uncover what lies beneath the surface. Be part of the exploration and reach out to us for more details! #DiPIA2024 #SPR #IRBM

From 𝗼𝗿𝗮𝗹 𝗱𝗲𝗹𝗶𝘃𝗲𝗿𝘆, to 𝗼𝗿𝘁𝗵𝗼𝗴𝗼𝗻𝗮𝗹 𝗽𝗿𝗼𝘁𝗲𝗰𝘁𝗶𝗻𝗴 𝗴𝗿𝗼𝘂𝗽𝘀 for side chains, to 𝘀𝘂𝘀𝘁𝗮𝗶𝗻𝗮𝗯𝗹𝗲 𝗽𝗲𝗽𝘁𝗶𝗱𝗲 𝘀𝘆𝗻𝘁𝗵𝗲𝘀𝗶𝘀, the 37th EPS proved to be a wealth of information for our peptide scientists, who continually implement new learnings and innovation into ongoing and future discovery programs. What do you think is one of the most interesting 𝗮𝗱𝘃𝗮𝗻𝗰𝗲𝘀 𝗼𝗿 𝘁𝗿𝗲𝗻𝗱𝘀 𝗶𝗻 𝗽𝗲𝗽𝘁𝗶𝗱𝗲 𝘀𝗰𝗶𝗲𝗻𝗰𝗲? 🗨️ Check out this edition of “𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝗕𝗶𝘁𝗲𝘀” by IRBM, and share your ideas in the comments! 🎤 Martina Tripepi and Sonia Del Rizzo #peptidescience #drugdiscovery #discoverybites #IRBM

🏅 IRBM 𝗝𝗼𝗶𝗻𝘀 𝘁𝗵𝗲 𝗘𝗹𝗶𝘁𝗲 𝗖𝗶𝗿𝗰𝗹𝗲 𝗼𝗳 𝗯𝗶𝗼𝗰𝗿𝗮𝘁𝗲𝘀 𝗖𝗲𝗿𝘁𝗶𝗳𝗶𝗲𝗱 𝗟𝗮𝗯𝗼𝗿𝗮𝘁𝗼𝗿𝗶𝗲𝘀! IRBM is proud to be the 𝗳𝗶𝗿𝘀𝘁 𝗹𝗮𝗯 𝗶𝗻 𝗜𝘁𝗮𝗹𝘆 certified by biocrates life sciences ag, showcasing our commitment to innovation and scientific excellence. 💡 𝗔𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗕𝗶𝗼𝗺𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 Our advanced #metabolomics platform provides for the analysis of plasma and urine samples for biomarker discovery, from the 𝗲𝗮𝗿𝗹𝘆 𝘀𝘁𝗮𝗴𝗲𝘀 𝗼𝗳 𝗱𝗿𝘂𝗴 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝘁𝗵𝗿𝗼𝘂𝗴𝗵 𝘁𝗮𝗿𝗴𝗲𝘁-𝗿𝗲𝗹𝗲𝘃𝗮𝗻𝘁 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘀𝘁𝘂𝗱𝘆 𝗺𝗼𝗻𝗶𝘁𝗼𝗿𝗶𝗻𝗴, with high sensitivity and minimal sample volumes. 𝗜𝗻 𝗹𝗲𝘀𝘀 𝘁𝗵𝗮𝗻 𝗮 𝘄𝗲𝗲𝗸, using advanced tools, we can quickly and accurately analyze: // 80+ samples // 107 small molecules and 523 lipids // 630 metabolites relevant to key biological functions ✨𝗝𝗼𝗶𝗻 𝗨𝘀 𝗶𝗻 𝗕𝗶𝗼𝗺𝗮𝗿𝗸𝗲𝗿 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 Are you fascinated by the prospect of discovering new #biomarkers? Step onto our platform for targeted metabolomics and discuss with us how we can support your portfolio of ideas. Together, we can revolutionize the way new biomarkers are discovered. Special thanks to our pharmacology team for their dedication to making this certification happen! 📸 Roberto Speziale #drugdiscovery #IRBM

While part of our team is actively engaging with peers at EFMC-ISMC in Italy, our exceptional BD members, including Betsy McKibben and Michael Ziebell, are driving collaborative efforts in the US, focusing on how best to advance our clients' preclinical drug discovery goals through year's end. Drug discovery is a collective effort, and no matter which side of the Atlantic you’re on, someone from IRBM is always ready to support you. PS – we’re expanding our BD team in various locations throughout the US, so check out our careers page if you think you may be a good candidate! #drugdiscovery #bostonbiotech #IRBM #collaboration

EFMC-ISMC is already off to a great start here in Rome, and we want to highlight a few 𝗺𝘂𝘀𝘁-𝘀𝗲𝗲 𝘀𝗲𝘀𝘀𝗶𝗼𝗻𝘀 𝗮𝗻𝗱 𝗲𝘃𝗲𝗻𝘁𝘀: 🪧 𝗣𝗼𝘀𝘁𝗲𝗿 𝗽𝗿𝗲𝘀𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻: Compound collection management: Dynamic fully automated platform and operative workflow for high throughput screening – P615 // 𝗠𝗼𝗻𝗱𝗮𝘆, 𝗦𝗲𝗽𝘁𝗲𝗺𝗯𝗲𝗿 𝟮 𝗳𝗿𝗼𝗺 𝟱:𝟯𝟬 𝗣𝗠 𝘁𝗼 𝟳:𝟬𝟬 𝗣𝗠 // Poster session 1 // Laura Mangiardi, Principal Research Scientist 🗣️ 𝗢𝗿𝗮𝗹 𝗽𝗿𝗲𝘀𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻: Evolution Towards Clinical Candidate MK-0616: Next Generation Oral Tricyclic Peptide PCSK9 Inhibitors for LDL-Lowering and Coronary Heart Diseases // 𝗧𝘂𝗲𝘀𝗱𝗮𝘆, 𝗦𝗲𝗽𝘁𝗲𝗺𝗯𝗲𝗿 𝟯, 𝟮𝟬𝟮𝟰 | 𝟭𝟭:𝟰𝟱 𝗔𝗠 // Session 9, Drug Discovery Projects – Trends in Peptide Drug Discovery // Danila Branca, Principal Research Investigator 🗣️ 𝗢𝗿𝗮𝗹 𝗽𝗿𝗲𝘀𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻: The Discovery of I-1000233, a Potent Brain Permeable and Orally Bioavailable SHP2 Allosteric Inhibitor // 𝗪𝗲𝗱𝗻𝗲𝘀𝗱𝗮𝘆, 𝗦𝗲𝗽𝘁𝗲𝗺𝗯𝗲𝗿 𝟰, 𝟮𝟬𝟮𝟰 | 𝟭𝟭:𝟮𝟱 𝗔𝗠 // Session 16, Drug Discovery Projects – Highlights in Medicinal Chemistry // Alessia Petrocchi, Principal Research Investigator 🎉 Banquet dinner (Sponsored by IRBM): Exclusive event at the stunning Villa Miani // 𝗪𝗲𝗱𝗻𝗲𝘀𝗱𝗮𝘆, 𝗦𝗲𝗽𝘁𝗲𝗺𝗯𝗲𝗿 𝟰𝘁𝗵 | 𝟴:𝟬𝟬 𝗣𝗠 𝗕𝗲 𝘀𝘂𝗿𝗲 𝘁𝗼 𝘃𝗶𝘀𝗶𝘁 𝘂𝘀 𝗮𝘁 𝗕𝗼𝗼𝘁𝗵 𝟮𝟱 during the exhibition to meet our team and discuss how we can support your drug discovery endeavors. #efmcismc2024 #medicinalchemistry #drugdiscovery #IRBM

We're #hiring a new Jr Research Scientist in Pomezia, Latium. Apply today or share this post with your network.

🔬 𝗘𝘃𝗲𝗿𝘆𝗼𝗻𝗲 𝗸𝗻𝗼𝘄𝘀 𝘁𝗵𝗮𝘁 𝗼𝗻𝗹𝘆 𝗮 𝗳𝗿𝗮𝗰𝘁𝗶𝗼𝗻 𝗼𝗳 𝗱𝗿𝘂𝗴 𝗰𝗮𝗻𝗱𝗶𝗱𝗮𝘁𝗲𝘀 𝗺𝗮𝗸𝗲 𝗶𝘁 𝘁𝗼 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹𝘀, 𝗼𝗳𝘁𝗲𝗻 𝗱𝘂𝗲 𝘁𝗼 𝗰𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀 𝗶𝗻 𝘁𝗵𝗲 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝘀𝘁𝗮𝗴𝗲.   The key to success is 𝘀𝗲𝗹𝗲𝗰𝘁𝗶𝗻𝗴 𝘁𝗵𝗲 𝗿𝗶𝗴𝗵𝘁 𝘁𝗮𝗿𝗴𝗲𝘁 and working with a team that can expertly manage every step to identify a compound that 𝗰𝗮𝗻 𝗽𝗿𝗼𝗴𝗿𝗲𝘀𝘀 𝘁𝗼 𝗰𝗮𝗻𝗱𝗶𝗱𝗮𝘁𝗲 𝗻𝗼𝗺𝗶𝗻𝗮𝘁𝗶𝗼𝗻.   At IRBM our strength lies in our end-to-end approach, bringing together an exceptionally talented team of 60+ medicinal and peptide chemists co-located with target biology and pharmacology experts, all under one roof.   With decades of experience in 𝘀𝗺𝗮𝗹𝗹 𝗺𝗼𝗹𝗲𝗰𝘂𝗹𝗲𝘀 and over 35 years of work in 𝗽𝗲𝗽𝘁𝗶𝗱𝗲𝘀, we are uniquely equipped to support your discovery program, ensuring your compound is thoroughly validated and poised for success as it approaches the pre-IND stage.   We’re excited to bring this expertise to the 𝗫𝗫𝗩𝗜𝗜𝗜 𝗘𝗙𝗠𝗖 𝗜𝗻𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗦𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 𝗼𝗻 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗮𝗹 𝗖𝗵𝗲𝗺𝗶𝘀𝘁𝗿𝘆 from September 1-5, 2024, in Rome, Italy.   Our experts, including Alessia Petrocchi, Danila Branca, and Laura Mangiardi, will share insights on SHP2 inhibitors, peptide-based therapeutics, and compound management strategies. 🌟 A special mention goes to the 𝗦𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 𝗕𝗮𝗻𝗾𝘂𝗲𝘁 𝗼𝗻 𝗪𝗲𝗱𝗻𝗲𝘀𝗱𝗮𝘆, 𝗦𝗲𝗽𝘁𝗲𝗺𝗯𝗲𝗿 4, at Villa Miani. This beautiful venue, offering stunning views of the eternal city, is the perfect setting for meaningful discussions about science and innovation.   We’re excited to connect with fellow experts and celebrate the future of medicinal chemistry. 🔔 Stay tuned for more updates!   #MedicinalChemistry #EFMCISMC2024 #DrugDiscovery #IRBM #ScientificResearch

Our journey as 𝗽𝗲𝗽𝘁𝗶𝗱𝗲 𝗱𝗿𝘂𝗴 𝗵𝘂𝗻𝘁𝗲𝗿𝘀 at IRBM has been shaped by the dedication and collaboration of our talented team. At the upcoming 37th European Peptide Symposium, you can meet Elisabetta Bianchi and Stefania Colarusso, who have been working together for many years to advance the field of peptide chemistry. During the Symposium: 📅 On August 27, Elisabetta Bianchi will present her work on "𝘾𝙝𝙚𝙢𝙞𝙘𝙖𝙡 𝙀𝙫𝙤𝙡𝙪𝙩𝙞𝙤𝙣 𝙤𝙛 𝙇𝙖𝙘𝙩𝙖𝙢 𝘾𝙤𝙣𝙨𝙩𝙧𝙖𝙞𝙣𝙚𝙙 𝙈𝙖𝙘𝙧𝙤𝙘𝙮𝙘𝙡𝙚𝙨: 𝙊𝙧𝙖𝙡 𝙏𝙧𝙞𝙘𝙮𝙘𝙡𝙞𝙘 𝙋𝙚𝙥𝙩𝙞𝙙𝙚 𝙋𝘾𝙎𝙆9 𝙄𝙣𝙝𝙞𝙗𝙞𝙩𝙤𝙧𝙨 𝙛𝙤𝙧 𝙇𝘿𝙇-𝙇𝙤𝙬𝙚𝙧𝙞𝙣𝙜 𝙖𝙣𝙙 𝘾𝙤𝙧𝙤𝙣𝙖𝙧𝙮 𝙃𝙚𝙖𝙧𝙩 𝘿𝙞𝙨𝙚𝙖𝙨𝙚𝙨" 📅 On August 30, Stefania Colarusso will present "𝙊𝙪𝙧 𝙟𝙤𝙪𝙧𝙣𝙚𝙮 𝙖𝙨 𝙥𝙚𝙥𝙩𝙞𝙙𝙚 𝙙𝙧𝙪𝙜 𝙝𝙪𝙣𝙩𝙚𝙧𝙨 𝙖𝙩 𝙄𝙍𝘽𝙈" at the workshop “Navigating Entrepreneurship and Technology Transfer in Peptide Discovery and Development” Join us in supporting our 𝗣𝗲𝗽𝘁𝗶𝗱𝗲 𝗖𝗵𝗲𝗺𝗶𝘀𝘁𝗿𝘆 𝗧𝗲𝗮𝗺 as they share the contributions they have made toward advancements in the field, and reach out to them, Sonia Del Rizzo, Martina Tripepi, Ali Hoseini, PhD, MBA, or Meg Sweeney if you’d like to meet at the symposium! #EPS2024 #IRBM #ScienceTalks

⚛️ At the 30th 𝗜𝗻𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 𝗼𝗻 𝗠𝗮𝗴𝗻𝗲𝘁𝗶𝗰 𝗥𝗲𝘀𝗼𝗻𝗮𝗻𝗰𝗲 𝗶𝗻 𝗕𝗶𝗼𝗹𝗼𝗴𝗶𝗰𝗮𝗹 𝗦𝘆𝘀𝘁𝗲𝗺𝘀 (#ICMRBS) in Seoul, we’re thrilled to be among the top researchers exploring the advancements in magnetic resonance within biological systems. It’s a unique opportunity to engage with leading experts shaping the future of this field. We’re passionate about how 𝗡𝘂𝗰𝗹𝗲𝗮𝗿 𝗠𝗮𝗴𝗻𝗲𝘁𝗶𝗰 𝗥𝗲𝘀𝗼𝗻𝗮𝗻𝗰𝗲 (NMR) technology drives innovation in drug discovery by offering unparalleled precision in structural biology. Leveraging advanced NMR, at IRBM we provide deep insights into molecular interactions, enabling the identification and optimization of lead compounds with high affinity and selectivity. 👉 Our poster on the "Discovery of a novel HTT ligand with preferential binding to polyQ expanded HTT Exon1", a study performed in collaboration with CHDI Foundation, sparked meaningful discussions, showcasing the critical role NMR plays in ligand discovery and characterization. We’re looking forward to continued exchanges with the community and new collaborations in pushing the boundaries of drug discovery. Alessandro Piai Michele Luche #ICMRBS2024 #StructuralBiology #NMR #DrugDiscovery #IRBM #Biotech